Apellis Total Assets from 2010 to 2025

APLS Stock

USD 24.14 0.01 0.04%

Apellis Pharmaceuticals Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 470.8 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2013-12-31

Previous Quarter

901.9 M

Current Value

885.1 M

Quarterly Volatility

379.6 M

Yuan Drop

Covid

Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 42.4 M or Selling General Administrative of 526.1 M, as well as many indicators such as Price To Sales Ratio of 5.29, Dividend Yield of 0.0 or PTB Ratio of 18.84. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.

For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Latest Apellis Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Apellis Pharmaceuticals over the last few years. Total assets refers to the total amount of Apellis Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Apellis Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Apellis Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 885.05 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Apellis Total Assets Regression Statistics

	Arithmetic Mean	351,424,338
	Geometric Mean	93,382,885
	Coefficient Of Variation	107.93
	Mean Deviation	334,554,930
	Median	203,533,559
	Standard Deviation	379,286,463
	Sample Variance	143858.2T
	Range	955.4M
	R-Value	0.84
	Mean Square Error	44791.6T
	R-Squared	0.71
	Significance	0.000042
	Slope	67,099,369
	Total Sum of Squares	2157873.3T

Apellis Total Assets History

	2025	470.8 M
	2024	885.1 M
	2023	788.7 M
	2022	760.2 M
	2021	881.8 M
	2020	960.6 M
	2019	389.2 M

Other Fundumenentals of Apellis Pharmaceuticals

Intangibles To Total Assets

Apellis Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Debt	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.89	-0.58	-0.81	0.74	0.51	0.99	1.0	0.87	0.85	0.98	0.89	0.7	0.9	0.81	-0.86	0.97	-0.79	0.86	-0.56	-0.73
Total Stockholder Equity	0.89		-0.52	-0.75	0.72	0.5	0.82	0.89	0.85	0.95	0.8	0.84	0.6	0.7	0.74	-0.79	0.81	-0.72	0.77	-0.54	-0.68
Net Debt	-0.58	-0.52		0.28	-0.28	0.24	-0.58	-0.6	-0.37	-0.49	-0.54	-0.48	0.08	-0.41	-0.06	0.52	-0.5	0.67	-0.31	-0.05	0.34
Retained Earnings	-0.81	-0.75	0.28		-0.98	-0.84	-0.8	-0.8	-0.95	-0.76	-0.87	-0.84	-0.73	-0.88	-0.69	0.77	-0.78	0.57	-0.97	0.89	0.96
Accounts Payable	0.74	0.72	-0.28	-0.98		0.82	0.72	0.74	0.94	0.75	0.8	0.82	0.66	0.83	0.6	-0.76	0.69	-0.57	0.93	-0.88	-0.95
Net Receivables	0.51	0.5	0.24	-0.84	0.82		0.49	0.5	0.78	0.54	0.58	0.63	0.76	0.67	0.63	-0.53	0.5	-0.27	0.78	-0.89	-0.75
Total Liab	0.99	0.82	-0.58	-0.8	0.72	0.49		0.99	0.84	0.79	0.99	0.87	0.7	0.92	0.8	-0.84	0.97	-0.78	0.84	-0.54	-0.72
Total Current Assets	1.0	0.89	-0.6	-0.8	0.74	0.5	0.99		0.87	0.86	0.97	0.89	0.68	0.9	0.8	-0.86	0.96	-0.8	0.84	-0.54	-0.73
Common Stock	0.87	0.85	-0.37	-0.95	0.94	0.78	0.84	0.87		0.9	0.89	0.95	0.78	0.92	0.72	-0.88	0.82	-0.71	0.91	-0.84	-0.89
Net Tangible Assets	0.85	0.95	-0.49	-0.76	0.75	0.54	0.79	0.86	0.9		0.78	0.9	0.67	0.76	0.69	-0.84	0.8	-0.75	0.74	-0.63	-0.69
Property Plant Equipment	0.98	0.8	-0.54	-0.87	0.8	0.58	0.99	0.97	0.89	0.78		0.89	0.72	0.95	0.79	-0.86	0.95	-0.76	0.9	-0.63	-0.8
Capital Surpluse	0.89	0.84	-0.48	-0.84	0.82	0.63	0.87	0.89	0.95	0.9	0.89		0.75	0.93	0.69	-0.96	0.83	-0.86	0.79	-0.68	-0.73
Long Term Debt	0.7	0.6	0.08	-0.73	0.66	0.76	0.7	0.68	0.78	0.67	0.72	0.75		0.81	0.88	-0.66	0.77	-0.45	0.7	-0.8	-0.6
Long Term Debt Total	0.9	0.7	-0.41	-0.88	0.83	0.67	0.92	0.9	0.92	0.76	0.95	0.93	0.81		0.73	-0.87	0.89	-0.74	0.86	-0.74	-0.79
Net Invested Capital	0.81	0.74	-0.06	-0.69	0.6	0.63	0.8	0.8	0.72	0.69	0.79	0.69	0.88	0.73		-0.63	0.85	-0.46	0.76	-0.62	-0.57
Short Long Term Debt	-0.86	-0.79	0.52	0.77	-0.76	-0.53	-0.84	-0.86	-0.88	-0.84	-0.86	-0.96	-0.66	-0.87	-0.63		-0.8	0.95	-0.74	0.58	0.67
Net Working Capital	0.97	0.81	-0.5	-0.78	0.69	0.5	0.97	0.96	0.82	0.8	0.95	0.83	0.77	0.89	0.85	-0.8		-0.71	0.81	-0.59	-0.7
Short Term Debt	-0.79	-0.72	0.67	0.57	-0.57	-0.27	-0.78	-0.8	-0.71	-0.75	-0.76	-0.86	-0.45	-0.74	-0.46	0.95	-0.71		-0.55	0.31	0.48
Capital Stock	0.86	0.77	-0.31	-0.97	0.93	0.78	0.84	0.84	0.91	0.74	0.9	0.79	0.7	0.86	0.76	-0.74	0.81	-0.55		-0.81	-0.94
Current Deferred Revenue	-0.56	-0.54	-0.05	0.89	-0.88	-0.89	-0.54	-0.54	-0.84	-0.63	-0.63	-0.68	-0.8	-0.74	-0.62	0.58	-0.59	0.31	-0.81		0.87
Short Term Investments	-0.73	-0.68	0.34	0.96	-0.95	-0.75	-0.72	-0.73	-0.89	-0.69	-0.8	-0.73	-0.6	-0.79	-0.57	0.67	-0.7	0.48	-0.94	0.87

Click cells to compare fundamentals

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	885.1 M	470.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC